Physician profile
Matthew E Levy
NPI 1255481180
$150,166.53
in general payments reported to CMS, 2019-2025
17 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $11K · 2021: $30K · 2022: $34K · 2023: $14K · 2024: $5,997 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $2,127 · Travel and Lodging: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,637.19 |
| Food and Beverage | $2,127.29 |
| Travel and Lodging | $1,403.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $148,545.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $219.71 | 2019-2024 | Lyumjev, Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $177.54 | 2019-2025 | |
| Insulet Corporation | $151.92 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Ascendis Pharma Endocrinology INC | $125.00 | 2025 | Yorvipath |
| Abbott Laboratories | $123.79 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $120.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.00 | 2019 | |
| Beta Bionics, INC. | $114.03 | 2023 | Ilet Bionic Pancreas |
| Amgen INC. | $90.14 | 2019 | |
| Medtronic Minimed, INC. | $86.15 | 2019 | |
| Sequel Med Tech, LLC | $54.86 | 2025 | Twiist |
| Valeritas, INC. | $42.67 | 2019 | |
| Corcept Therapeutics | $30.65 | 2025 | Korlym |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $22.70 | 2024 | Cequr Simplicity |
| Medtronic, INC. | $16.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.